NCT05665283View on ClinicalTrials.gov

A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

January 18, 2023

Study Completion Date

August 8, 2023

Conditions

Bioequivalency

Interventions

DRUG

Ensartinib Hydrochloride

oral ALK inhibitor

Trial Locations (1)

66219

ICON - Early Development Services, Lenexa

All Listed Sponsors

lead

Xcovery Holdings, Inc.

INDUSTRY